Skip to content


Libtayo (cemiplimab) is an antibody pharmaceutical. Cemiplimab was first approved as Libtayo on 2018-09-28. It is used to treat squamous cell carcinoma in the USA. It has been approved in Europe to treat squamous cell carcinoma. The pharmaceutical is active against programmed cell death protein 1.
Trade Name Libtayo
Common Name Cemiplimab
Indication squamous cell carcinoma
Drug Class Monoclonal antibodies: immunomodulating
Get full access now